How Do Peptides Work? Receptor Signaling Explained

TL;DR

How do peptides work? They are short amino acid chains that act as signaling molecules: a peptide binds a specific receptor and tells a cell what to do, instead of acting as the finished hormone. - GHRH-receptor peptides like CJC-1295 signal the pituitary to release its own growth hormone, and the effect on GH and IGF-1 can last for days (Teichman et al., 2006). - Ghrelin-receptor peptides like ipamorelin bind GHS-R to trigger a growth hormone pulse (Raun et al., 1998); the same receptor family also drives appetite and glucose effects (Nass et al., 2008). - GLP-1 receptor agonists slow gastric emptying and reduce appetite; in the STEP 1 trial, semaglutide produced about 15 percent mean weight loss (Wilding et al., 2021). - Repair-signaling peptides like BPC-157 are proposed to work through VEGFR2 and nitric oxide pathways, but the strong evidence is from animal models and human data is very limited (Sikiric et al., PMC7096228).

Peptides are widely discussed, but most explanations stop at "they are short proteins." The real question is mechanism: what does a peptide bind, and what does that binding tell the body to do? Below are the four mechanism families that cover most research peptides, each with the receptor it targets and the evidence behind it.

What is a peptide, in one sentence?

A peptide is a short chain of amino acids, usually under about 50 residues, that carries a message to a specific receptor rather than building tissue like a large protein or acting as a finished steroid hormone.

Amino acids are the building blocks. A long chain folds into a protein. A short chain stays small and mobile, which lets it fit into a receptor pocket and pass along a signal. The body already makes hundreds of natural peptides, including insulin, GLP-1, and growth hormone releasing hormone. Most research peptides copy or modify one of these natural messengers.

How do peptides actually work in the body?

Most peptides work by binding a receptor on the surface of a cell, which flips a molecular switch inside that cell and tells it to release a hormone, shift its metabolism, or start a repair process.

Think of it as a lock and key. The receptor sits on the cell surface (many are G protein coupled receptors). When the peptide docks, the receptor changes shape and activates second messengers inside the cell, such as cyclic AMP, which cascade into an action. The important point: the peptide is the messenger, not the payload. CJC-1295 does not add growth hormone to the blood; it tells the pituitary to release its own (Teichman et al., 2006).

How is a peptide different from a steroid hormone?

Steroids are fat soluble and pass straight through the cell membrane to bind receptors inside the cell and change gene expression, while most peptides are water soluble and act at the cell surface as a short outside signal.

Because steroids act on DNA transcription, their effects tend to build slowly and linger. Because peptides act at the surface through fast second messengers, their effects can be quick and often depend on how long the peptide survives in the blood, which is its half-life. This surface action is also why most peptides are injected: stomach acid and gut enzymes break the amino acid chain, so a swallowed peptide often never reaches the bloodstream intact.

How does receptor binding turn into a real effect?

Binding is only step one; the receptor then fires an internal signaling cascade, and the size and length of the effect depend on how selective the peptide is and how long it stays bound and circulating.

Selectivity is a big reason two peptides that target the same system can behave differently. Ipamorelin is a selective growth hormone secretagogue, so it raises GH with little effect on cortisol or prolactin (Raun et al., 1998). A less selective compound can pull other signals along with it. The other factor is duration, covered in the half-life section below.

How do GHRH-receptor peptides like CJC-1295 work?

They mimic growth hormone releasing hormone and bind the GHRH receptor on the pituitary, prompting the gland to release its own stored growth hormone.

In a controlled study, CJC-1295 produced sustained increases in GH and IGF-1 (Teichman et al., 2006). Tesamorelin is another GHRH analog: Falutz et al., 2007 reported about a 15 percent reduction in visceral adipose tissue in a study population, versus a rise on placebo. Because these peptides prompt the body's own release rather than replacing the hormone, some natural feedback control stays in place.

How do ghrelin-receptor peptides like ipamorelin work?

They act as ghrelin mimetics that bind the growth hormone secretagogue receptor (GHS-R1a), which triggers a growth hormone pulse and, through the same receptor, influences hunger and glucose.

Ipamorelin is described as a selective GH secretagogue (Raun et al., 1998), and a review of GHS-R (Yin et al., 2014; PMC3975427) lays out the receptor's broader roles in appetite and metabolism. That breadth matters. MK-677 is an oral ghrelin mimetic that raised GH and IGF-1, but Nass et al., 2008 reported that it also raised fasting glucose and lowered insulin sensitivity, a reminder that receptor effects are not always narrow.

How do GLP-1 receptor agonists work?

They bind the GLP-1 receptor to slow how fast the stomach empties, reduce appetite signaling in the brain, lower glucagon, and support glucose-dependent insulin release.

A 2024 mechanistic review covers these pathways in detail (Liu, Frontiers in Endocrinology 2024; doi:10.3389/fendo.2024.1431292). The human outcomes are large: semaglutide produced about 15 percent mean weight loss in STEP 1 (Wilding et al., 2021), and tirzepatide, which hits both GIP and GLP-1 receptors, reached up to about 22.5 percent in SURMOUNT-1 (Jastreboff et al., 2022). Trials also reported weight regain after stopping (Wilding et al., 2022; Aronne et al., 2024), which shows the receptor signal has to keep firing for the effect to hold.

How do tissue-repair peptides like BPC-157 work?

BPC-157 is proposed to speed repair by promoting new blood vessel growth through the VEGFR2 receptor and the nitric oxide (eNOS) pathway, though this mechanism rests mainly on animal studies.

The angiogenesis and VEGFR2 model is drawn largely from animal research, and human data is very limited (Sikiric et al., PMC7096228). To be clear, this is a proposed pathway rather than a proven human effect. When a peptide's mechanism sits mostly in animal models, the right framing is "research in animals suggests," not "this works in people."

What are the main peptide mechanism families at a glance?

Most research peptides fall into a few families defined by the receptor they bind and the signal they send.

Why does half-life matter for how a peptide works?

Half-life is how long a peptide stays active in the blood, and it decides whether a peptide delivers a brief pulse or a sustained signal.

Some peptides are engineered to last. CJC-1295 with a drug affinity complex binds to albumin, which is one reason Teichman et al., 2006 measured sustained GH and IGF-1 over days rather than minutes. A short-acting ghrelin mimetic, by contrast, gives a sharper and shorter pulse. This is also why study protocols vary so much from one compound to the next. The dosing figures in published papers reflect what those studies and commonly studied research protocols report; they are educational, not a prescription or a personal recommendation. How much of any peptide a person uses, and how often, is a medical decision for a qualified clinician, not a schedule you should copy from a paper.